|130th MAINE LEGISLATURE|
|LD 675||LR 1633(02)|
|An Act To Protect Maine Consumers from Unsupported Price Increases on Prescription Medicines by Creating an Independent Review Process|
|Fiscal Note for Bill as Amended by Committee Amendment " "|
|Committee: Health Coverage, Insurance and Financial Services|
|Fiscal Note Required: Yes|
|Current biennium revenue increase - Other Special Revenue
Minor revenue increase - General Fund
|FY 2021-22||FY 2022-23||Projections FY 2023-24||Projections FY 2024-25|
|Other Special Revenue Funds||$500||$500||$500||$500|
|Correctional and Judicial Impact Statements|
|This bill may
increase the number of civil suits filed in the court system.
The additional workload associated with the minimal number of new cases filed in the court system does not require additional funding at this time.
The collection of additional filing fees may increase General Fund and other dedicated revenue by minor amounts.
|Fiscal Detail and Notes|
|This bill includes base allocations of $500 beginning in fiscal year 2021-22 to establish the Unsupported Prescription Drug Price Increases Fund in the Office of the Attorney General (OAG) with a stated purpose to "benefit customers or to offset health care costs to consumers". Revenue credited to the fund will come from any fines assessed on presciption drug manufacturers for violations set forth in the bill. The OAG will face increased costs due to the anticipated number of new actions related to prescription drug violation. The fund may be used to offset those costs. The Office of Treasurer of State and the Maine Health Data Organization may request the OAG to reimburse expenses they have incurred for their roles in fulfilling the purposes of the bill and the OAG may grant requests only if there will be no significant negative impact on the ability of the fund to meet its stated purpose. No estimate is made of how much fine revenue will be credited to the fund.|